RecruitingPhase 2NCT04192253
Treatment of Locally Advanced VULvar CArcinoma in a Neoadjuvant Setting With Carboplatin and Paclitaxel Chemotherapy (VULCANize)
Sponsor
The Netherlands Cancer Institute
Enrollment
51 participants
Start Date
Jan 14, 2020
Study Type
INTERVENTIONAL
Conditions
Summary
Vulvar cancer is a rare malignancy. Surgery is the treatment of choice, but frequently causes invalidating and chronic postoperative morbidity, especially in patients with high stage disease. Theoretically, downstaging with neoadjuvant chemotherapy could shrink the tumour, making surgical treatment less extensive thereby diminishing the chance for morbidity.
Eligibility
Sex: FEMALEMin Age: 18 Years
Inclusion Criteria10
- Woman k 18 years
- Signed and written informed consent.
- Histologically confirmed squamous cell vulvar carcinoma
- World Health Organization performance status of 0-2
- Adequate hematological function
- Adequate hepatic function
- Adequate renal function
- Negative pregnancy test for woman of childbearing potential
- measurable disease by physical examination
- TNM stage T2, any N, MO
Exclusion Criteria4
- Vulvar cancer other than squamous cell carcinoma at biopsy
- Previous radiotherapy of the vulva, groins or pelvis
- Patients with metastasis limited to the pelvic lymph nodes, who can be primarily operated with curative intent
- Other diagnosis of malignancy or evidence of other malignancy for 5 years before screening for this study
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGPaclitaxel and Carboplatin
Paclitaxel 175 mg/m2 and Carboplatin AUC 5 in a 3 weekly schedule
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04192253